GL1X · GenesisL1 explorer

Research workbench

Thiazolone-acylsulfonamides as novel HCV NS5B polymerase allosteric inhibitors: convergence of structure-based drug design and X-ray crystallographic study

Analyse Thiazolone-acylsulfonamides as novel HCV NS5B polymerase allosteric inhibitors… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
2O5D
Type
protein
Length
1,120 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
HCV
EC
2.7.7.48
UniProt
P26663
Ligands
VR1
Pockets
15 · best druggability 0.80

Structure

x-ray diffraction · 2 distinct chains · 49% helix, 16% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AHCV (EC 2.7.7.48)protein55949% helix, 16% strandP26663
BHCV (EC 2.7.7.48)protein56149% helix, 16% strandP26663

Ligands and binding sites

  • VR1 · (2S)-2-({(5Z)-5-[(5-ethyl-2-furyl)methylene]-4-oxo-4,5-dihydro-1,3-thiazol-2-yl}amino)-2-(4-fluorophenyl)-N-[(4-nitrophenyl)sulfonyl]acetamide · ligand · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

15 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
110950.800.8284empty
210370.800.8182empty
311010.760.7959empty
41120.500.8120empty
51080.480.8020empty

Interfaces

1 interface between chains.

  • A–B · 546 Ų buried · 10 hydrogen bonds · protein-protein

Compared structures

  • 2O5D · Thiazolone-acylsulfonamides as novel HCV NS5B polymerase allosteric inhibitors… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.